Background Patients with depression and comorbid obesity may be more prone to weight
modulating and cardiovascular side effects of selected antidepressants (AD). It is important …

Introduction: Depression is a serious disorder that brings a tremendous health and
economic burden. Many antidepressants (AD) have obesogenic effects, increasing the …

Background Depression and obesity are debilitating conditions representing an enormous
health and economic burden worldwide. Depression is common among patients with excess …

Objective Obesity and major depressive disorder often co-occur. However, differences
between obese and normal-weight depressed patients and the moderating effect of obesity …

Weight gain is a common side-effect of medications used to treat major depressive disorder
(MDD). We sought to estimate the frequency of weight gain for obesogenic medications …

Objective The aim of this study was to describe the age‐and gender‐specific incidence of
depression, the dose‐response relationship between BMI and risk of depression (Cox …

Background Obesity, depressive disorders and antidepressant drugs are associated with
increased mortality, cardiovascular disease, diabetes, fractures and falls. We explored …

Background: Weight gain as an adverse effect of monotherapy of antidepressant has been
well-studied. The effects of augmentation therapy involving multiple antidepressants, on …

There is significant association between obesity and depression. Naltrexone/Bupropion
(NB) is indicated for treatment of overweight and obesity (BMI≥ 27 kg/m 2 with a comorbidity …

Objective: Overweight and obese patients commonly suffer from depression and choice of
depression therapy may alter weight. We conducted a cohort study to investigate whether …